These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 4553733)

  • 21. [Prolonged chimerism of lymphoid tissue obtained in adult mice using cyclophosphamide].
    Pevnitskiĭ LA; Solov'ev VV; Fontalin LN; Andreson RK
    Biull Eksp Biol Med; 1971 Aug; 72(8):71-5. PubMed ID: 4939474
    [No Abstract]   [Full Text] [Related]  

  • 22. [Effect of cyclophosphamide on neuroblastoma and the bone marrow function in the experimental studies].
    Ohkawa M
    Hokkaido Igaku Zasshi; 1983 Nov; 58(6):561-74. PubMed ID: 6368346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Host repopulation of endothelium.
    Williams GM; Krajewski CA; Dagher FJ; ter Haar AM; Roth JA; Santos GW
    Transplant Proc; 1971 Mar; 3(1):869-72. PubMed ID: 4937983
    [No Abstract]   [Full Text] [Related]  

  • 24. Symposium on bone marrow transplantation: experimental aspects in canines.
    Thomas ED; Storb R; Epstein RB; Rudolph RH
    Transplant Proc; 1969 Mar; 1(1):31-3. PubMed ID: 5002661
    [No Abstract]   [Full Text] [Related]  

  • 25. Regulation of plasma erythropoietin levels in mice with impaired responsiveness to erythropoietin.
    Fried W; Gregory SA; Knospe WH; Trobaugh FE
    J Lab Clin Med; 1971 Sep; 78(3):449-56. PubMed ID: 4937301
    [No Abstract]   [Full Text] [Related]  

  • 26. [Recovery of immunological functions in lethally irradiated mice grafted with preirradiated hematopoietic bone marrow].
    Beaumariage ML; Haot J; Betz EH
    C R Seances Soc Biol Fil; 1972; 166(6):965-8. PubMed ID: 4569449
    [No Abstract]   [Full Text] [Related]  

  • 27. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of antilymphocyte serum on the redifferentiation of hematopoietic stem cells by syngeneic lymphocytes].
    Golovistikov IN; Bliakher MS; Zykov IuV
    Dokl Akad Nauk SSSR; 1972 Jun; 204(4):980-2. PubMed ID: 4557586
    [No Abstract]   [Full Text] [Related]  

  • 29. Immunosuppression versus immunity in syngeneic and allogeneic tumours.
    Vlachov K; Nouza K
    Neoplasma; 1973; 20(1):3-12. PubMed ID: 4573871
    [No Abstract]   [Full Text] [Related]  

  • 30. Studies on transplantation of bone marrow and spleen cells.
    Munakata K
    Nagoya J Med Sci; 1966 Dec; 29(2):129-38. PubMed ID: 4862013
    [No Abstract]   [Full Text] [Related]  

  • 31. [Quantitative aspects of modern radiation immunology and problem of the action of radiation on intercellular cooperative processes].
    Petrov RV; Koval'chuk LV; Cheredeev AN
    Radiobiologiia; 1971; 11(4):483-94. PubMed ID: 4939572
    [No Abstract]   [Full Text] [Related]  

  • 32. [Increased efficacy of allogenic bone marrow transplantation].
    Fedotenkov AG; Danilova LA; Ignasheva LP
    Biull Eksp Biol Med; 1982 Aug; 94(8):104-8. PubMed ID: 6751429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of delayed mortality (secondary disease) in allogeneic radiation chimeras receiving bone marrow from aged mice.
    Chen MG; Price GB; Makinodan T
    J Immunol; 1972 May; 108(5):1370-8. PubMed ID: 4555115
    [No Abstract]   [Full Text] [Related]  

  • 34. Bone marrow transplantation in chronic GvHD and autoimmune diseases.
    Andolina M; Maximova N; Rabusin M; Parco S; Colovic M; Jankovic G
    Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():145-7. PubMed ID: 8932817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
    Burns ER; Scheving LE
    Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
    [No Abstract]   [Full Text] [Related]  

  • 36. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
    Duerst RE; Horan JT; Liesveld JL; Abboud CN; Zwetsch LM; Senf ES; Constine LS; Raubertas RF; Passarell JA; DiPersio JF
    Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of AKR leukemia by transplanting H-2-incompatible allogeneic bone marrow requires the maintenance of chimerism.
    Emeson EE; Weintraub FM
    Transplant Proc; 1981 Mar; 13(1 Pt 2):774-7. PubMed ID: 7022946
    [No Abstract]   [Full Text] [Related]  

  • 38. Some questions of non-H-2 transplantation tolerance in mice.
    Nĕmec M; Nouza K
    Folia Biol (Praha); 1971; 17(2):86-96. PubMed ID: 4930299
    [No Abstract]   [Full Text] [Related]  

  • 39. The influence of graft-versus-host reactivity, lymphocyte depletion, and cell dose on allogeneic bone marrow engraftment.
    Glass B; Uharek L; Gaska T; Gassmann W; Löffler H; Müller-Ruchholtz W
    Bone Marrow Transplant; 1993; 12 Suppl 3():S41-7. PubMed ID: 8124257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eosinophilia after allogeneic bone marrow transplantation using busulfan and cyclophosphamide conditioning regimen.
    Arslan O; Akan H; Koç H; Beksaç M; Ilhan O; Ozcan M; Yalçín S; Gürman G; Konuk N; Uysal A
    Bone Marrow Transplant; 1996 Jul; 18(1):261. PubMed ID: 8832034
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.